Wockhardt Pharma stock: If you want to earn money in the stock market, it is very important to be alert. You should keep an eye on those companies which are engaged in a special project or are trying to make something that can bring a big change in human life. There is one such company, which was experimenting and researching on a drug for about 15 years, which will cure serious diseases very fast in the coming time. In just one year, this pharma company has earned 10 times the money for the investors. We are talking about Wockhardt Pharma. Even today its stock has jumped 5.03 percent and closed at Rs 1519.20.

Investors are wondering why Wockhardt's stock has jumped so much today? So let us tell you that the main reason for this is the approval of the company's new drug Miknaf (Nafithromycin) by the Indian drug regulator, Central Drugs Standard Control Organization (CDSCO). This drug will treat community-acquired bacterial pneumonia (CABP), which is a serious disease that spreads infection in the lungs.

What is special about Miknaf medicine?
The specialty of Miknaf medicine is that it shows a very good effect in just three days, by taking it once a day. It is also effective on those bacteria which are not cured by common medicines. This medicine has now been successful in India, America, Europe and South Africa after 15 years of non-human and human trials.

After this announcement, Wockhardt's shares made a highest level of Rs 1,580 on Friday. Yesterday (Thursday) it closed at Rs 1,445.75. With today's jump, the market capitalization of Wockhardt Pharma Company has crossed Rs 25,000 crore.

CABP is a serious problem worldwide.
CABP is a disease that affects millions of people every year. Globally, 23 percent of its victims are from India. The main causes of this disease are bacteria such as S. Pneumoniae and H. Influenzae. Apart from this, bacteria such as mycoplasma, chlamydia and legionella can also cause it.

FIIs target Walkhart's stock
According to the data available on Moneycontrol, the company's stock had fallen to Rs 145 in March 2023. Currently it is trading at a price of more than Rs 1500. Meaning the investment has been multiplied 10 times in less than 2 years. However, the company is still about Rs 500 away from its all-time high. In March 2013, Walkhart Pharma's stock had made a high of Rs 1999.27.

This pharma stock has been in the eyes of big foreign investors since March 2023. FIIs have increased their investment every quarter. In March 2023, they had 2.78 percent stake, while according to the data of November 2024, FIIs have 6.62 percent stake.

DIIs made huge gains
Similarly, big domestic investors have also increased their stake to 7.09 per cent in November 2024 as compared to 3.11 per cent in March 2024. The promoters of the company have definitely reduced their stake, but have also got the pledged shares released. In March 2023, the promoters had 59.31 per cent stake, out of which a little more than 65 per cent shares were pledged, meaning they were pledged. But in November 2024, their stake is 49.09 per cent, and the percentage of pledged shares has remained only 36.1.